All In Biotech

Drug Trial Radar · NCT05994001

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Two Stage, Multi-center Trial of Candonilimab in Combination With LM-302 for Treatment of Patients With Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

78

Actual

Start

Aug 1, 2023

Primary completion

May 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Shanghai Zhongshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Xuhui Central Hospital, Shanghai; Shanghai Geriatric Medical Center; Affiliated Hospital of Jining Medical University
First posted
Aug 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this clinical study, we will evaluate the efficacy and safety of cardonilimumab (PD1 monoclonal antibody and CTLA-4 monoclonal antibody bisspecific antibodies) and LM-302 (Claudin18.2-ADC) in Claudin18.2-positive advanced BTC patients who have progressed after SOC and PD1/PD-L1 monoclonal antibody treatment.

Conditions

  • Biliary Tract Cancer
  • Candonilimab
  • Claudin 18.2

Interventions

  • cardonilizumabDrug

    cardonilizumab:PD1 and CTLA-4 bispecific antibody

  • LM-302Drug

    LM-302 :ClAUDIN 18.2-ADC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR(Phase II)Time frame: 24months
  2. Incidence of Treatment-Emergent Adverse Events(Phase I)Time frame: 24months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan hospital, Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.